Academic Journal
Lymph Node-Targeted PLGA-EgG1Y162 Nanovaccine for Synergistic Immunity Against Echinococcus granulosus Infection.
| Τίτλος: | Lymph Node-Targeted PLGA-EgG1Y162 Nanovaccine for Synergistic Immunity Against Echinococcus granulosus Infection. |
|---|---|
| Συγγραφείς: | Aizezi M; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China.; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu, People's Republic of China., Tuohetali A; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China.; College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, Xinjiang, People's Republic of China., Maimaiti M; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China.; College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, Xinjiang, People's Republic of China., Li X; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China.; College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, Xinjiang, People's Republic of China., Song Y; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China.; College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, Xinjiang, People's Republic of China., Chen X; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China.; College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, Xinjiang, People's Republic of China., Chen G; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China., Abula S; College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi, Xinjiang, People's Republic of China., Gao H; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China., Yan R; MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu, People's Republic of China., Aimulajiang K; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China. |
| Πηγή: | International journal of nanomedicine [Int J Nanomedicine] 2026 Sep 02; Vol. 21, pp. 620325. Date of Electronic Publication: 2026 Sep 02 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Auckland : DOVE Medical Press |
| Ιατρικοί όροι (MeSH): | Nanovaccines*/chemistry , Echinococcus granulosus*/immunology , Echinococcosis*/prevention & control , Echinococcosis*/immunology , Lymph Nodes*/immunology , Lymph Nodes*/drug effects , Polyglycolic Acid*/chemistry , Lactic Acid*/chemistry , Antigens, Helminth*/immunology , Antigens, Helminth*/chemistry , Antigens, Helminth*/administration & dosage, CD4-Positive T-Lymphocytes/immunology ; Dendritic Cells/immunology ; Dendritic Cells/drug effects ; Animals ; Polylactic Acid-Polyglycolic Acid Copolymer ; Mice ; Female ; Mice, Inbred BALB C ; Protein Subunit Vaccines |
| Περίληψη: | Background: Cystic echinococcosis (CE), a zoonosis caused by Echinococcus granulosus, severely endangers human and animal health in western pastoral China. Conventional surgery and chemotherapy suffer from high recurrence and toxic side effects, so immunization is urgently needed for CE prevention. Methods: We constructed a PLGA nanovaccine loading EgG1Y162 antigen (PLGA-EgG1Y162) via double emulsion-solvent evaporation. Its physicochemical features, DC activation, in vivo lymph node retention, immune response, anti-infection protection and CD4⁺ T cell transcriptome were comprehensively detected. Results: The nanovaccine showed uniform spherical morphology with an average particle size of 394 nm and 79% encapsulation efficiency, presenting favorable sustained-release performance and excellent biocompatibility. In vitro experiments verified that PLGA-EgG1Y162 was efficiently taken up by dendritic cells and effectively facilitated DC maturation. In vivo tracking demonstrated that the nanovaccine achieved prolonged retention within lymph nodes. Compared with the free antigen group and Freund's adjuvant-adjuvanted group, PLGA-EgG1Y162 induced significantly higher and longer-lasting antigen-specific IgG antibodies, markedly upregulated splenic IFN-γ, IL-4, IL-10 and TNF-α expression, and maintained elevated proportions of splenic CD4⁺ and CD8⁺ T cells. At 16 and 24 weeks post infection, vaccinated mice had remarkably fewer hepatic cysts, reduced liver-to-body weight ratios and lower serum transaminase levels, with relatively intact hepatic tissue architecture. Transcriptomic data illustrated that the vaccine reshaped CD4⁺ T cell transcriptional profiles, alleviated infection-triggered chronic inflammation, and suppressed aberrant activation of hepatic autophagy-related genes. Conclusion: PLGA-EgG1Y162 realizes lymph node-targeted sustained antigen delivery to elicit balanced long-lasting humoral and cellular immunity, producing prominent protection against E. granulosus. This work offers a promising immunoprophylactic candidate for cystic echinococcosis. (© 2026 Aizezi et al.) |
| Competing Interests: | The authors declare no conflicts of interest. |
| References: | Nanoscale. 2024 Jun 27;16(25):12149-12162. (PMID: 38833269) Pharm Res. 2024 Feb;41(2):305-319. (PMID: 38332390) Front Pharmacol. 2025 Jun 11;16:1600525. (PMID: 40567359) Parasite. 2024;31:56. (PMID: 39311470) Front Immunol. 2025 Oct 16;16:1686959. (PMID: 41181113) Int Immunopharmacol. 2024 Sep 10;138:112538. (PMID: 38924865) Small. 2008 Sep;4(9):1453-8. (PMID: 18680094) Polymers (Basel). 2011 Sep 1;3(3):1377-1397. (PMID: 22577513) Cell Microbiol. 2019 Oct;21(10):e13084. (PMID: 31290228) Front Immunol. 2024 Oct 01;15:1475280. (PMID: 39416787) ACS Pharmacol Transl Sci. 2025 Aug 08;8(9):3182-3198. (PMID: 40969898) Vaccines (Basel). 2024 Dec 20;12(12):. (PMID: 39772100) Front Cell Infect Microbiol. 2024 May 16;14:1334211. (PMID: 38817444) Pharmaceutics. 2022 Dec 06;14(12):. (PMID: 36559223) Front Cell Infect Microbiol. 2026 Feb 19;16:1747682. (PMID: 41798755) Acta Trop. 2023 Jul;243:106925. (PMID: 37080264) J Hepatol. 2011 Nov;55(5):1025-33. (PMID: 21354448) RSC Adv. 2021 Mar 3;11(16):9433-9449. (PMID: 35423427) Curr Drug Deliv. 2021;18(10):1378-1390. (PMID: 33970845) Nanomedicine. 2020 Oct;29:102257. (PMID: 32610072) Eur J Immunol. 1995 Mar;25(3):823-9. (PMID: 7705414) ACS Infect Dis. 2024 Nov 8;10(11):3939-3950. (PMID: 39463350) Mol Immunol. 2018 Feb;94:183-189. (PMID: 29328998) Vaccines (Basel). 2023 Jan 30;11(2):. (PMID: 36851182) Braz J Med Biol Res. 2024 Nov 25;57:e13139. (PMID: 39607201) Bioimpacts. 2018;8(1):39-52. (PMID: 29713601) Oncotarget. 2017 Sep 8;8(57):97009-97024. (PMID: 29228589) Lancet Infect Dis. 2018 Sep;18(9):946. (PMID: 30152358) BMJ. 2012 Jun 11;344:e3866. (PMID: 22689886) Front Immunol. 2025 Aug 27;16:1663012. (PMID: 40936913) Clin Microbiol Rev. 2019 Feb 13;32(2):. (PMID: 30760475) Int J Nanomedicine. 2025 Jan 08;20:309-325. (PMID: 39802377) Nanomedicine (Lond). 2017 Mar;12(5):491-510. (PMID: 28181470) Nat Immunol. 2024 Sep;25(9):1731-1741. (PMID: 39164479) Biologicals. 2024 Feb;85:101737. (PMID: 38101003) J Immunol. 2022 Jan 15;208(2):407-419. (PMID: 34965963) Int J Nanomedicine. 2023 Jun 08;18:3069-3085. (PMID: 37312930) J Vis Exp. 2008 Jul 25;(17):. (PMID: 19066520) |
| Contributed Indexing: | Keywords: Echinococcus granulosus; EgG1Y162; PLGA; immune response; nanovaccine |
| Substance Nomenclature: | 0 (Nanovaccines) 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) 26009-03-0 (Polyglycolic Acid) 33X04XA5AT (Lactic Acid) 0 (Antigens, Helminth) 0 (Protein Subunit Vaccines) |
| Entry Date(s): | Date Created: 20260907 Date Completed: 20260907 Latest Revision: 20260908 |
| Update Code: | 20260908 |
| PubMed Central ID: | PMC13546691 |
| DOI: | 10.2147/IJN.S620325 |
| PMID: | 42703412 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1178-2013 |
|---|---|
| DOI: | 10.2147/IJN.S620325 |